Seeking Alpha

Lilly gets tentative approval for diabetes drug

  • The FDA grants tentative approval for Eli Lilly (LLY +0.5%) and Boehringer Ingelheim's Basaglar (insulin glargine injection) as a treatment to improve glycemic control in adults with type 2 diabetes and in combination with prandial insulin in adult and pediatric patients with type 1 diabetes.
  • While the FDA has determined that Basaglar meets all the criteria for market clearance, it is tentative because of the automatic 30-month stay due to Sanofi's (SNY -0.8%) patent infringement suit. The agency cannot issue final approval until the stay ends (mid-2016) or unless the court finds in Lilly's favor before then.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs